2022 / 02

Next Paper
DOI: 10.24075/brsmu.2022.015
Copyright: © 2022 by the authors. Licensee: Pirogov University.
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (CC BY).

ORIGINAL RESEARCH

Experience of tocilizumab in hospital patients with moderate COVID-19

Burgasova OA1,2, Dolinniy SV3, Tetova VB1, Ogarkova DA2, Odnoralov MA1, Bakalin VV1, Smetanina SV3, Antipyat NA3, Taranova MV4
About authors

1 Peoples’ Friendship University of Russia, Moscow, Russia

2 Gamaleya National Research Center for Epidemiology and Microbiology, Moscow, Russia

3 Clinical Hospital for Infectious Diseases №1, Moscow, Russia

4 Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Correspondence should be addressed: Olga A. Burgasova
Volokolamskoe sh., 47, str. 8, korp. 5, Moscow, 125310, Russia; ur.liam@avosagrubaglo

About paper

Author contribution: OA Burgasova — initiative and design, supervision of the clinical part of the study, writing of the manuscript; SV Dolinniy — literature review, clinical observations, data processing; VB Tetova — literature review, editing of the manuscript; DA Ogarkova — statistical analysis; MA Odnoralov, VV Baсalin — clinical observations, processing of clinical and laboratory data; SV Smetanina — concept; NA Antipyat — supervision of the clinical part of the study, MV Taranova — literature review, data processing.

Compliance with ethical standards: the study was approved by the ethics committee at the Clinical Hospital for Infectious Diseases №1 (Protocol 1 of January 11, 2021); all participants provided informed consent for the study.

Received: 2022-03-10 Accepted: 2022-04-03 Published online: 2022-04-15
|
  1. WHO Coronavirus (COVID-19) Dashboard (2021). Available from: https://covid19.who.int/ (Accessed 19 October, 2021).
  2. Song P, Li W, Xie J, et al. Cytokine storm induced by SARSCoV-2. Clin Chim Acta. 2020; 509: 280–7. DOI: 10.1016/j. cca.2020.06.017.
  3. Zhao Z, Wei Y, Tao C. An enlightening role for cytokine storm in coronavirus infection. Clin Immunol. 2021; 222: DOI: 10.1016/j. clim.2020.108615.
  4. Moradian N, Gouravani M, Salehi MA, et al. Cytokine release syndrome: inhibition of pro-inflammatory cytokines as a solution for reducing COVID-19 mortality. Eur Cytokine Netw. 2020; 31 (3): 81–93. DOI: 10.1684/ecn.2020.0451.
  5. Pum A, Ennemoser M, Adage T, Kungl AJ. Cytokines and Chemokines in SARS-CoV-2 Infections—Therapeutic Strategies Targeting Cytokine Storm. Biomolecules. 2021; 11 (1): DOI: 10.3390/biom11010091.
  6. Nasonov E, Samsonov M. The role of Interleukin 6 inhibitors in therapy of severe COVID-19. Biomed Pharmacother. 2020; 131: DOI: 10.1016/j.biopha.2020.110698.
  7. Zhou Z, Price C. Overview on the use of IL6 agents in the treatment of patients with cytokine release syndrome (CRS) and pneumonitis related to COVID-19 disease. Expert Opin Investig Drugs. 2020; 29 (12): 1407–12. DOI: 10.1080/13543784.2020.1840549.
  8. Chen J, Zhang L, Hou H, et al. Interleukin 6 signaling blockade treatment for cytokine release syndrome in COVID 19 (Review). Exp Ther Med. 2021; 21 (1): 24. DOI: 10.3892/etm.2020.9456.
  9. Moore JB, June CH. Cytokine release syndrome in severe COVID-19. Science. 2020; 368 (6490): 473–4. DOI: 1126/ science. Abb 8925.
  10. Kumar A, Sharma A, Tirpude NV, Sharma S, Padwad YS, Kumar S. Pharmaco-immunomodulatory interventions for averting cytokine storm-linked disease severity in SARS-CoV-2 infection. Inflammopharmacology. 2022 Jan 20: 1–27. DOI: 10.1007/ s10787-021-00903-x. Online ahead of print. PMID: 35048262.
  11. Jiang Y, Rubin L, Peng T, Liu L, Xing X, Lazarovici P, Zheng W. Cytokine storm in COVID-19: from viral infection to immune responses, diagnosis and therapy. Int J Biol Sci. 2022 Jan 1; 18 (2): 459–72. DOI: 10.7150/ijbs.59272. eCollection 2022. PMID: 35002503.
  12. Group A-TL-CS. A Neutralizing Monoclonal Antibody for Hospitalized Patients With Covid-19. N Engl J Med. 2020; 384 (10): 905–14. DOI: 10.1056/NEJMoa2033130.
  13. Weinreich DM, Sivapalasingam S, Norton T, Ali S, Gao H, Bhore R, et al. REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19. N Engl J Med. 2020; 384 (3): 238–51. DOI: 10.1056/NEJMoa2035002.
  14. Verderese JP, Stepanova M, Lam B, Racila A, Kolacevski A, Allen D, et al. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. Clin Infect Dis. 2021; DOI: 10.1093/cid/ciab579.
  15. Chen P, Nirula A, Heller B, Gottlieb RL, Boscia J, Morris J, et al. SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients With Covid-19. N Engl J Med. 2021; 384 (3): 229–37. DOI: 10.1056/NEJMoa2029849.
  16. Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. Rev Recent Clin Trials. 2021; 16 (2): 138–45. DOI: 10.2174/15748871 15666200917110954.PMID: 32940187 Review.
  17. Tleyjeh IM, Kashour Z, Riaz M, Hassett L, Veiga VC, Kashour T. Efficacy and safety of tocilizumab in COVID-19 patients: a living systematic review and meta-analysis, first update. Clin Microbiol Infect. 2021 Aug; 27 (8): 1076–82. DOI: 10.1016/j.cmi.2021.04.019. Epub 2021 Apr 27.
  18. Cortegiani A, Ippolito M, Greco M, Granone V, Protti A, Gregoretti C, et al. Rationale and evidence on the use of tocilizumab in COVID-19: a systematic review. Pulmonology. 2021 Jan-Feb; 27 (1): 52–66. DOI: 10.1016/j.pulmoe.2020.07.003. Epub 2020 Jul 20. PMID: 32713784.
  19. Salvarani C, Dolci G, Massari M, et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A Randomized Clinical Trial. JAMA Intern Med. 2021; 181 (1): 24–31. DOI: 10.1001/ jamainternmed.2020.6615.
  20. Stone JH, Frigault MJ, Serling-Boyd NJ, et al. Efficacy of Tocilizumab in Patients Hospitalized with Covid-19. N Engl J Med. 2020; 383 (24): 2333–44. DOI: 10.1056/NEJMoa2028836.
  21. Verderese JP, Stepanova M, Lam B, Racila A, Kolacevski A, Allen D, et al. Neutralizing Monoclonal Antibody Treatment Reduces Hospitalization for Mild and Moderate COVID-19: A Real-World Experience. Clin Infect Dis. 2021; DOI: 10.1093/cid/ciab579.
  22. Vremennye metodicheskie rekomendacii # 14 ot 27.12.2021 «Profilaktika, diagnostika i lechenie novoj koronavirusnoj infekcii (COVID-19)». Russian.
  23. Antwi-Amoabeng D, Kanji Z, Ford B, Beutler BD, Riddle MS, Siddiqui F. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review. J Med Virol. 2020 Nov; 92 (11): 2516–22. DOI: 10.1002/jmv.26038. Epub 2020 Jun 9.